BioNTech SE (BNTX)

業務介紹

生物新藥公司BioNTech SE開發和商業化用於癌症和其他傳染病的免疫療法。該公司正在開發FixVac產品候選藥物,包括:

- BNT111正處於II期臨床試驗,用於治療晚期黑色素瘤;
- BNT112正處於I/IIa期臨床試驗,用於治療前列腺癌;
- BNT113正處於II期臨床試驗,用於治療HPV陽性的頭頸部癌;
- BNT114正處於I期臨床試驗,用於治療三陰性乳腺癌;
- BNT115正處於I期臨床試驗,用於治療卵巢癌;
- BNT116正處於臨床前階段,用於治療非小細胞肺癌。

該公司還開發新抗原特異性免疫療法,如Autogene cevumeran (BNT122),正處於II期臨床試驗用於一線治療黑色素瘤,以及I期a/I期b臨床試驗用於治療多種實體瘤。此外,該公司還開發mRNA腫瘤內注射免疫療法(包括SAR441000)、嵌合抗原受體T細胞免疫療法(如BNT211和BNT221)、檢查點免疫調節劑(如GEN1046和GEN1042)、單克隆抗體(如BNT321)、小分子免疫調節劑(如BNT411)、新冠肺炎和流感預防疫苗,以及罕見疾病蛋白替代療法。

該公司與Genentech、Sanofi、Genmab、輝瑞、上海復星醫藥和Regeneron等公司有合作關係。BioNTech SE於2008年成立,總部位於德國美因茨。



BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

公司網址

https://www.biontech.de